2011
Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle Albumin-Bound PaclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-Bound PaclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albumin
2007
Pilot study of regional, hepatic intra‐arterial paclitaxel in patients with breast carcinoma metastatic to the liver
Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, Wallace MJ, Kim EE, Curley SA, Hortobagyi GN, Mavligit G. Pilot study of regional, hepatic intra‐arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer 2007, 109: 2190-2196. PMID: 17464952, DOI: 10.1002/cncr.22672.Peer-Reviewed Original ResearchConceptsDominant liver metastasisBreast carcinomaTaxane exposureLiver metastasesAntitumor activityCommon treatment-related toxicitiesHepatic intra-arterial therapyPatient underwent liver resectionCourses of paclitaxelUnderwent liver resectionMean patient ageTreatment-related toxicityHepatic arterial infusionIntra-arterial therapyProcedure-related complicationsBreast carcinoma metastaticMetastatic breast carcinomaIntra-arterial catheterPercutaneous transfemoral approachTime of treatmentHepatic infusionStable diseaseCarcinoma metastaticPaclitaxel therapyTaxane therapy